Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)

Similar Items

• Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial
  od: Akamatsu, Hiroaki, i dr.
  Izdano: (2018)
• Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)
  od: Takahama, Takayuki, i dr.
  Izdano: (2016)
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
  od: Mok, T.S., i dr.
  Izdano: (2016)
• Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
  od: Matsuo, Norikazu, i dr.
  Izdano: (2016)
• EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
  od: Yamada, Teppei, i dr.
  Izdano: (2013)